Preclinical News and Research

RSS

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

20 Jan 2011

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011

Study validates MultiStem as potential stem cell therapy for spinal cord injury

Case Western Reserve University School of Medicine and Athersys, Inc. announced a joint scientific study on spinal cord injury will be published today in the January issue of The Journal of Neuroscience.

20 Jan 2011

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

4SC AG, a drug discovery and development company, today announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.

20 Jan 2011

Theraclone, Pfizer enter multi-year research and development collaboration

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that they have entered into a multi-year research and development collaboration with Pfizer. The collaboration will use Theraclone's I-STAR™ technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

19 Jan 2011

Case Western Reserve, Athersys enter partnership for scientific study on spinal cord injury

19 Jan 2011

Positive preliminary results from Soligenix's SGX202 in GARS model

Soligenix, Inc., a late-stage biopharmaceutical company, announced today promising preliminary results from a preclinical study of SGX202 in a canine gastrointestinal acute radiation syndrome model.

19 Jan 2011

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Following a successful Phase 1 study for safety, researchers at MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 2 clinical trial testing the ability of a human monoclonal antibody they developed to prevent hepatitis C virus infection of a donor liver in transplant patients.

19 Jan 2011

Harbor Biosciences signs development agreements for HE2000, HE3235 and HE3286 with CIPI

Harbor BioSciences, Inc., a leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals, announced it has licensed the research and development and commercialization rights for three of its products, exclusively in the People's Republic of China and Hong Kong, to China State Institute of Pharmaceutical Industry (CIPI).

18 Jan 2011

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

PROLOR Biotech, Inc., today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation.

18 Jan 2011

Seordus recieves Japanese patent for SER100

The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.

18 Jan 2011

Study finds miRNAs inhibits prostate cancer metastasis

A small slice of RNA inhibits prostate cancer metastasis by suppressing a surface protein commonly found on prostate cancer stem cells. A research team led by scientists at The University of Texas MD Anderson Cancer Center reported today in an advance online publication at Nature Medicine.

18 Jan 2011

Platelet-rich plasma shows a promising biologic treatment for myocardial infarction: Study

Researchers at the Stanford University School of Medicine, in collaboration with BioParadox, Inc., have published data supporting the use of platelet-rich plasma as a promising biologic treatment for myocardial infarction.

18 Jan 2011

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

Diamyd has dosed the first subject in a Phase II clinical trial in the United States evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain.

17 Jan 2011

BIOTRONIK announces FDA IDE approval and first patient enrollment for TOCCASTAR clinical trial

BIOTRONIK SE Co. & KG highlights two key milestones toward receiving premarket approval (PMA) of the TactiCath, a novel technology for treating atrial fibrillation (AF): FDA IDE (investigational device exemption) approval and the first patient enrollment of the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical trial.

14 Jan 2011

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

Cell Therapeutics, Inc. today announced that it has entered into a securities purchase agreement to sell, subject to certain closing conditions, up to $25.0 million of shares of its Series 8 Non-Convertible Preferred Stock, warrants to purchase up to 22,563,177 shares of common stock and an additional investment right to purchase up to $25.0 million of shares of its Series 9 Convertible Preferred Stock, in a registered offering to a single life sciences institutional investor.

13 Jan 2011

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded two preclinical services contracts totaling $17.4 million by the National Heart, Lung, and Blood Institute, one of the National Institutes of Health.

13 Jan 2011

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

MedImmune, the global biologics unit of AstraZeneca PLC and Micromet, today announced the initiation of a Phase 1 trial of MEDI-565 in patients with advanced gastrointestinal cancers. MEDI-565 is a BiTE antibody designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express carcinoembryonic antigen.

13 Jan 2011

PLoS Neglected Tropical Diseases features Inovio’s Chikungunya DNA vaccine

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper highlighting positive results from Inovio's multi-antigen Chikungunya virus (CHIKV) DNA vaccine in PLoS Neglected Tropical Diseases.

12 Jan 2011

Researchers design new electronic technology equipment for detecting live cellular processes

The electronic technology equipment designed by the researchers- which is in patent process-is based on molecular imaging, a type of biomedical imaging capable of detecting live cellular processes. "These techniques differ from conventional medical imaging in that the information they show is function not form, which means that they are capable of showing the malfunctioning of an organ before the malfunction turns into an anatomical change", Juan Jos- Vaquero explained.

12 Jan 2011

Preclinical News and Research

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Study validates MultiStem as potential stem cell therapy for spinal cord injury

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

Theraclone, Pfizer enter multi-year research and development collaboration

Case Western Reserve, Athersys enter partnership for scientific study on spinal cord injury

Positive preliminary results from Soligenix's SGX202 in GARS model

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Harbor Biosciences signs development agreements for HE2000, HE3235 and HE3286 with CIPI

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

Seordus recieves Japanese patent for SER100

Study finds miRNAs inhibits prostate cancer metastasis

Platelet-rich plasma shows a promising biologic treatment for myocardial infarction: Study

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

BIOTRONIK announces FDA IDE approval and first patient enrollment for TOCCASTAR clinical trial

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

PLoS Neglected Tropical Diseases features Inovio’s Chikungunya DNA vaccine

Researchers design new electronic technology equipment for detecting live cellular processes

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics